RNA Therapeutics & Delivery 1 article

RNA Therapeutics & Delivery covers therapeutic strategies that use RNA molecules or sequence-specific oligonucleotides to alter gene expression, protein production or RNA processing. The scope includes RNA interference, siRNA, antisense oligonucleotides, mRNA medicines, RNA vaccines and delivery systems such as lipid nanoparticles and GalNAc conjugates. It separates the molecular modality from named drugs, and distinguishes transcript degradation, splice modulation and transient mRNA expression as different mechanisms rather than interchangeable forms of RNA therapy.

Drug Discovery

October 2, 2026, 1:50 AM · 3 mins read

Novartis grabs exclusive global rights to Abogen's RNA drug in $7.8 billion deal

Novartis will pay up to $7.8 billion for exclusive access to Abogen's experimental RNA drug for autoimmune diseases, with options for more therapies. The deal starts with a $575 million upfront payment.